// App-Quantinova.ai

195 : Circulating tumor cell (CTC) detection, N-terminal androgen (AR) characterization, and PTEN loss in metastatic or advanced castration resistant prostate cancer (CRPC).

Researchers

Presenter

  • Shidong Jia

Principal Investigators

  • Sarah Baird

  • Amanda K. L. Anderson

  • Shannon L. Werner

  • Jane Petersen

  • Ling Huw

  • Dena C. Marrinucci

  • Premal H. Patel

Medical Centers

  • Genentech, Inc., South San Francisico, CA

  • Epic Sciences, Inc., San Diego, CA

  • Epic Sciences, Inc., San Diego, CA

  • Genentech, San Francisco, CA

  • Genentech, San Francisco, CA

  • Genentech, Redwood City, CA.

Locations

  • United States

Companies

  • Genentech, Inc.

  • EPIC SCIENCES, INC.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Phosphatase and tensin homolog

  • Circulating tumor cells

  • Cluster of differentiation 45

Drug/Treatment

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01485861

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved